cefixime

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.10 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	41 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	29.33 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	47 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.31 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.20 hours	Lombardo F, Berellini G, Obach RS

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	-2.777		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.839		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	0.378	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	2.099	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	48.100	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	52.930	%	High	1
herg	hERG pIC50	4.239	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	1.928	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	4.009	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	29.570	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CSF1R,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,HIPK2,IKBKB,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKAA1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70	77
kinase-selectivity-class	ACVR2B,AURKC,AXL,BRAF,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,IKBKB,JAK2,MAP2K6,MAP3K14,MAP3K2,MAPK12,MAPK7,MAPK8,PIM3,PRKAA1,PRKDC,STK33,SYK,TEK,TGFBR1,TTK,UHMK1	29
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.550		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	3.162		High	1
mppb	Mouse plasma protein binding (% unbound)	61.480		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.207		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	34.890	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	1.135	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	92.670	%	High	1
rppb	Rat plasma protein binding (% unbound)	21.480	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	866.962	uM	High	1

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	75.07	16.88	41	6122	37929	90584355
Gastroenteritis staphylococcal	42.62	16.88	7	6156	79	90622205
Clostridium difficile infection	42.56	16.88	28	6135	36217	90586067
Clostridium difficile colitis	42.42	16.88	25	6138	26681	90595603
Secretion discharge	36.57	16.88	19	6144	15877	90606407
Paraesthesia oral	36.06	16.88	24	6139	31635	90590649
Toxic epidermal necrolysis	35.47	16.88	24	6139	32504	90589780
Vaginal flatulence	34.62	16.88	17	6146	12621	90609663
Female genital tract fistula	34.48	16.88	19	6144	17849	90604435
Drug hypersensitivity	34.12	16.88	88	6075	463521	90158763
Radiculopathy	33.86	16.88	19	6144	18486	90603798
Pulmonary congestion	33.00	16.88	19	6144	19414	90602870
Stevens-Johnson syndrome	32.81	16.88	22	6141	29354	90592930
Proctitis	31.60	16.88	17	6146	15242	90607042
Vaginal discharge	30.33	16.88	18	6145	19446	90602838
Dysbiosis	30.31	16.88	9	6154	1693	90620591
Chronic sinusitis	29.44	16.88	19	6144	23783	90598501
Mucocutaneous candidiasis	29.10	16.88	4	6159	11	90622273
Premature baby	28.53	16.88	19	6144	25058	90597226
Panic attack	27.67	16.88	19	6144	26346	90595938
Biopsy colon abnormal	27.58	16.88	5	6158	104	90622180
Procedural pain	25.83	16.88	20	6143	33340	90588944
Ankylosing spondylitis	25.44	16.88	14	6149	13119	90609165
Gastrointestinal mucosa hyperaemia	24.19	16.88	5	6158	210	90622074
Erythema	23.96	16.88	50	6113	229196	90393088
Movement disorder	23.79	16.88	18	6145	29001	90593283
Frequent bowel movements	23.69	16.88	24	6139	56911	90565373
Clostridium test positive	23.42	16.88	10	6153	5391	90616893
Vaginal infection	22.07	16.88	11	6152	8429	90613855
Pulmonary mass	21.73	16.88	17	6146	28755	90593529
Drug reaction with eosinophilia and systemic symptoms	21.50	16.88	20	6143	42738	90579546
Malignant melanoma in situ	21.10	16.88	6	6157	970	90621314
Foetal growth restriction	20.97	16.88	11	6152	9369	90612915
Candida test positive	20.72	16.88	6	6157	1033	90621251
Oligohydramnios	20.66	16.88	10	6153	7191	90615093
Apraxia	19.88	16.88	7	6156	2255	90620029
Febrile neutropenia	19.49	16.88	37	6126	158312	90463972
Meniscus injury	19.39	16.88	10	6153	8227	90614057
Haematochezia	19.37	16.88	24	6139	70889	90551395
COVID-19	19.02	16.88	38	6125	168805	90453479
Neutropenia	18.93	16.88	45	6118	224859	90397425
Oral candidiasis	18.63	16.88	17	6146	35438	90586846
Off label use	18.50	16.88	133	6030	1102119	89520165
Anaemia	18.18	16.88	59	6104	352743	90269541
Colitis	18.03	16.88	23	6140	69919	90552365
Abdominal pain	17.61	16.88	63	6100	395658	90226626
Disorientation	17.27	16.88	18	6145	44096	90578188
Acute generalised exanthematous pustulosis	17.09	16.88	11	6152	13692	90608592
Circumoral oedema	17.07	16.88	4	6159	301	90621983
Tubulointerstitial nephritis	17.06	16.88	14	6149	25329	90596955
Atypical mycobacterial pneumonia	16.96	16.88	3	6160	54	90622230

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oral pustule	41.97	20.68	8	2708	236	42618383
Tracheobronchitis bacterial	32.22	20.68	5	2711	41	42618578
Pyrexia	29.37	20.68	72	2644	393970	42224649
Psoriatic arthropathy	27.31	20.68	18	2698	24949	42593670
Pulmonary congestion	26.62	20.68	15	2701	15715	42602904
Heat exhaustion	25.06	20.68	5	2711	188	42618431
Urticaria	24.91	20.68	27	2689	74009	42544610
Clostridium difficile colitis	22.46	20.68	15	2701	21237	42597382
Septic shock	21.81	20.68	28	2688	91644	42526975
Tendon pain	21.33	20.68	8	2708	3292	42615327
Carnitine deficiency	20.92	20.68	4	2712	120	42618499

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Clostridium difficile colitis	66.03	16.69	41	8221	43737	110537300
Pulmonary congestion	59.75	16.69	34	8228	30932	110550105
Secretion discharge	55.27	16.69	28	8234	20216	110560821
Toxic epidermal necrolysis	47.48	16.69	37	8225	56690	110524347
Panic attack	45.91	16.69	28	8234	28912	110552125
Oropharyngeal gonococcal infection	41.99	16.69	6	8256	21	110581016
Oral pustule	39.57	16.69	8	8254	273	110580764
Pulmonary mass	39.43	16.69	28	8234	37273	110543764
Stevens-Johnson syndrome	37.97	16.69	30	8232	46871	110534166
Movement disorder	37.73	16.69	27	8235	36377	110544660
Clostridium difficile infection	37.25	16.69	31	8231	52098	110528939
Clostridium test positive	35.50	16.69	17	8245	10876	110570161
Febrile neutropenia	35.34	16.69	75	8187	316692	110264345
Female genital tract fistula	34.20	16.69	19	8243	16500	110564537
Vaginal flatulence	33.74	16.69	17	8245	12127	110568910
Gastroenteritis staphylococcal	32.81	16.69	7	8255	312	110580725
Paraesthesia oral	32.68	16.69	24	8238	33647	110547390
Acute generalised exanthematous pustulosis	31.92	16.69	20	8242	21644	110559393
Dysbiosis	31.56	16.69	10	8252	2122	110578915
Erythema	31.34	16.69	68	8194	291379	110289658
Proctitis	31.08	16.69	18	8244	16909	110564128
Vaginal discharge	30.14	16.69	18	8244	17890	110563147
Macular degeneration	29.44	16.69	19	8243	21640	110559397
Radiculopathy	28.87	16.69	18	8244	19318	110561719
Oral candidiasis	28.67	16.69	25	8237	44735	110536302
Biopsy colon abnormal	27.74	16.69	5	8257	91	110580946
Chronic sinusitis	26.90	16.69	19	8243	25065	110555972
Pyrexia	26.75	16.69	135	8127	898130	109682907
Procedural pain	25.09	16.69	21	8241	35544	110545493
Pneumonia mycoplasmal	25.09	16.69	8	8254	1733	110579304
Tendon pain	24.10	16.69	11	8251	6315	110574722
Vaginal infection	23.34	16.69	11	8251	6793	110574244
Drug reaction with eosinophilia and systemic symptoms	22.22	16.69	29	8233	82066	110498971
Ankylosing spondylitis	21.97	16.69	14	8248	15598	110565439
Drug hypersensitivity	21.83	16.69	79	8183	454011	110127026
COVID-19	21.72	16.69	53	8209	245007	110336030
Neutropenia	21.35	16.69	69	8193	374551	110206486
Mucocutaneous candidiasis	21.14	16.69	4	8258	96	110580941
Tubulointerstitial nephritis	20.99	16.69	23	8239	54261	110526776
Agranulocytosis	20.21	16.69	24	8238	61736	110519301
Frequent bowel movements	18.98	16.69	25	8237	71365	110509672
Gastrointestinal mucosa hyperaemia	18.89	16.69	5	8257	563	110580474
Colitis	18.69	16.69	30	8232	102293	110478744
Candida test positive	18.60	16.69	6	8256	1349	110579688
Restless legs syndrome	18.33	16.69	15	8247	24611	110556426
Pseudomembranous colitis	17.91	16.69	9	8253	6382	110574655
Food protein-induced enterocolitis syndrome	17.59	16.69	3	8259	39	110580998
Haematochezia	17.30	16.69	31	8231	115493	110465544
Paralysis	17.15	16.69	12	8250	15588	110565449
Rash maculo-papular	16.73	16.69	24	8238	74198	110506839

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

cefixime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	J01DD08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD58	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01RA15	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	J01RA16	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
MeSH PA	D000097902	beta Lactam Antibiotics
MeSH PA	D000097911	Third Generation Cephalosporins
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:36047	antibacterial drug
CHEBI has role	CHEBI:64946	anti-HIV agent
CHEBI has role	CHEBI:88188	drug allergen

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Acute gonococcal urethritis	indication	29864006
Bronchitis	indication	32398004	DOID:6132
Streptococcal tonsillitis	indication	41582007
Upper respiratory infection	indication	54150009
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456
Acute bacterial bronchitis	indication	233598009
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Pharyngitis	indication	405737000	DOID:2275
Acute exacerbation of chronic bronchitis	indication	425748003
Moraxella Catarrhalis Acute Otitis Media	indication	703469002
Haemophilus Influenzae Bronchitis	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Streptococcus Pneumoniae Bronchitis	indication
Pneumonia due to Escherichia coli	off-label use	51530003
Acute bacterial sinusitis	off-label use	75498004
Haemophilus Parahaemolyticus Pneumonia	off-label use
Haemophilus Parainfluenzae Pneumonia	off-label use
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		IC50	4.24	WOMBAT-PK
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	Enzyme	P19174	PLCG1_HUMAN		IC50	5.92	CHEMBL
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Streptokinase A	Enzyme		STRP_STRP1		EC50	7.22	WOMBAT-PK

ID	Source
4019391	VUID
N0000147544	NUI
D00258	KEGG_DRUG
125110-14-7	SECONDARY_CAS_RN
25033	RXNORM
C0060400	UMLSCUI
CHEBI:472657	CHEBI
C04	PDB_CHEM_ID
CHEMBL1541	ChEMBL_ID
D020682	MESH_DESCRIPTOR_UI
DB00671	DRUGBANK_ID
10898	IUPHAR_LIGAND_ID
97I1C92E55	UNII
5362065	PUBCHEM_CID
233747	MMSL
4374	MMSL
d00072	MMSL
387536009	SNOMEDCT_US
96052006	SNOMEDCT_US
4019391	VANDF
002737	NDDF

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefixime	Human Prescription Drug Label	1	59651-647	CAPSULE	400 mg	ORAL	ANDA	24 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	64980-430	TABLET	400 mg	ORAL	ANDA	21 sections
Cefixime	Human Prescription Drug Label	1	65862-751	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	25 sections
Cefixime	Human Prescription Drug Label	1	65862-752	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	25 sections
CEFIXIME	Human Prescription Drug Label	1	67877-584	CAPSULE	400 mg	ORAL	ANDA	24 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-405	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-405	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-407	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-407	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-416	CAPSULE	400 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-416	CAPSULE	400 mg	ORAL	ANDA	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-423	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	68180-423	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2749	CAPSULE	400 mg	ORAL	ANDA	24 sections
CEFIXIME	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3221	CAPSULE	400 mg	ORAL	NDA authorized generic	25 sections
SUPRAX	HUMAN PRESCRIPTION DRUG LABEL	1	70934-079	CAPSULE	400 mg	ORAL	NDA	28 sections
Cefixime 400 mg	HUMAN PRESCRIPTION DRUG LABEL	1	83112-400	CAPSULE	400 mg	ORAL	ANDA	2 sections

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.45	acidic
pKa2	2.54	acidic
pKa3	3.24	Basic